Loading...
XASXPNV
Market cap888mUSD
Dec 23, Last price  
2.06AUD
1D
4.57%
1Q
-19.22%
Jan 2017
610.34%
Name

Polynovo Ltd

Chart & Performance

D1W1MN
XASX:PNV chart
P/E
270.51
P/S
13.79
EPS
0.01
Div Yield, %
0.00%
Shrs. gr., 5y
1.21%
Rev. gr., 5y
49.02%
Revenues
103m
+58.17%
01784,36600121,910388,2010112,56560,19622,3393,277,2043,620,1266,553,85214,043,82222,156,12329,157,92441,439,83965,241,468103,192,000
Net income
5m
P
-10,764,589-11,293,869-13,406,939-4,441,167-1,830,175-1,861,559-2,917,137-2,699,475-1,492,423-2,936,379-1,302,446-3,061,874-5,006,014-5,974,132-3,189,893-4,193,737-4,605,032-1,192,532-4,924,5395,261,000
CFO
4m
P
00000000-2,325,918-2,612,850-2,567,281-3,556,419-5,161,533-6,877,961-3,369,733-402,564-248,737-2,056,633-5,933,0673,683,000
Earnings
Feb 25, 2025

Profile

PolyNovo Limited develops medical devices in the United States, Australia, New Zealand, the United Kingdom, Ireland, Singapore, and internationally. The company offers NovoSorb Biodegradable Temporising Matrix, which is used in a fully debrided clean surgical wound to physiologically close the wound. It is also developing hernia devices for hernia repair and tissue reinforcement products; NovoSorb Dermal Beta Cell Implant to host pancreatic islets in the skin; and NovoSorb drug elution depots. The company was formerly known as Calzada Limited and changed its name to PolyNovo Limited in November 2014. PolyNovo Limited was incorporated in 1998 and is headquartered in Port Melbourne, Australia.
URL
https://polynovo.com/
IPO date
Nov 26, 1998
Employees
218
Domiciled in
AU
Incorporated in
AU

Valuation

Title
AUD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑062023‑062022‑062021‑062020‑062019‑062018‑062017‑062016‑062015‑06
Income
Revenues
103,192
58.17%
65,241
57.44%
41,440
42.12%
Cost of revenue
156,585
106,541
60,795
Unusual Expense (Income)
NOPBT
(53,393)
(41,299)
(19,355)
NOPBT Margin
Operating Taxes
(3,550)
(9)
42
Tax Rate
NOPAT
(49,843)
(41,291)
(19,396)
Net income
5,261
-206.83%
(4,925)
312.95%
(1,193)
-74.10%
Dividends
Dividend yield
Proceeds from repurchase of equity
52,051
180
BB yield
-4.91%
-0.02%
Debt
Debt current
2,535
1,890
1,788
Long-term debt
25,595
26,518
9,207
Deferred revenue
Other long-term liabilities
504
417
6,697
Net debt
(18,400)
(19,048)
4,545
Cash flow
Cash from operating activities
3,683
(5,933)
(2,057)
CAPEX
(2,897)
(1,528)
(492)
Cash from investing activities
(1,490)
(1,528)
5,858
Cash from financing activities
(3,170)
48,064
(5,388)
FCF
(53,793)
(53,664)
(17,662)
Balance
Cash
45,957
46,897
6,152
Long term investments
573
559
297
Excess cash
41,370
44,194
4,377
Stockholders' equity
72,124
65,383
17,715
Invested Capital
46,638
37,649
24,626
ROIC
ROCE
EV
Common stock shares outstanding
700,383
684,454
660,874
Price
2.45
58.06%
1.55
13.97%
1.36
-51.77%
Market cap
1,715,938
61.74%
1,060,904
18.04%
898,789
-51.80%
EV
1,697,538
1,041,856
903,335
EBITDA
(50,655)
(39,017)
(17,557)
EV/EBITDA
Interest
721
714
315
Interest/NOPBT